The results were presented yesterday at the American Heart Association’s High Blood Pressure Research 2012 Scientific Sessions.
ChromaDex’s (Irvine, CA) pTeroPure pterostilbene ingredient significantly reduced blood pressure in a recent study on adults. The patented pTeroPure is a nature-identical form of pterostilbene, an antioxidant found in blueberries.
In double-blind, placebo-controlled fashion, researchers from the University of Mississippi Medical Center assigned 80 adults to a high dose of pTeroPure (250 mg), a low dose of pTeroPure (50 mg), the low dose in combination with 100 mg of grape extract, or placebo. On average, participants were considered prehypertensive, with a mean systolic blood pressure of 127.4 mmHg and a mean diastolic blood pressure of 79.3 mmHg.
At the study’s close, subjects in the high-dose pterostilbene group showed significantly greater reductions in blood pressure compared to the placebo group. Specifically, the group showed reductions of 7.9 mmHg in systolic blood pressure and 7.33 mmHg in diastolic blood pressure.
By contrast, ChromaDex says, there wasn’t much change in subjects’ lipid profiles. The only significant change noted here was an increase in LDL cholesterol with pTeroPure-although this increase was less in participants on cholesterol-lowering medication and also was not seen in subjects who received the grape/pterostilbene combination. ChromaDex adds that there were also slight reductions in body weight in subjects not on cholesterol medication but on pTeroPure.
Following these results, pTeroPure was deemed to be a “promising ingredient in the area of cardiometabolics” by the study’s lead researcher Daniel M. Riche, PharmD, cardiometabolic clinic coordinator at the University of Mississippi School of Pharmacy.
Results of the study were presented at the American Heart Association’s High Blood Pressure Research 2012 Scientific Sessions.
Pterostilbene has been of interest in other areas of health as well, including cognitive function and antiaging. ChromaDex also recently launched its own line of dietary supplements featuring pTeroPure, called BluScience.
Meta-analysis does not find increased risk of bleeding events from omega-3 PUFA consumption
July 8th 2024Researchers reviewed 11 studies and found that there was no difference in the incidence of bleeding events between patients receiving omega-3 PUFAs and those not receiving them. High dose EPA consumption was associated with an elevated but modest risk.
Recent review states that pentadecanoic acid may support cellular stability for better longevity
June 25th 2024According to the paper’s author, Stephanie Venn-Watson, DVM, MPH, deficiency in pentadecanoic acid of ≤0.2% total circulating fatty acids increases the risk of ferroptosis, which a type of cell death cause by the peroxidation of fragile fatty acids in cell membranes that combines with iron thus increasing reactive oxygen species, and disabling mitochondria.
Recent review makes the case for testing omega-3 fatty acid levels in humans
May 23rd 2024The article commissioned by The Global Organization for EPA and DHA Omega-3s (GOED) reviewed the state of omega-3 fatty acid testing, highlighting the value of testing and the commercially available options for diagnostic testing.
Epax launches concentrated oil that combines omegas 3, 9, and 11
May 10th 2024The blend of long-chain polyunsaturated fatty acids and long-chain monounsaturated fatty acids combines the heart and brain health benefits of omegas-3s with the skin and metabolic health benefits of omegas 9 and 11.